Background: Linkage studies have provided evidence for a prostate cancer susceptibility locus on chromosome 17q. The mitochondrial protein prohibitin (PHB) is a plausible candidate gene based on its chromosomal location (17q21) and known function. Methods: All coding regions and intron/exon junctions of the PHB gene were sequenced in 32 men from families participating in the University of Michigan Prostate Cancer Genetics Project that demonstrated evidence of linkage to 17q markers. Results: Although a number of nucleotide variants were identified, no coding region substitutions were identified in any of the 32 men with prostate cancer from 32 unrelated multiplex prostate cancer families. Conclusions: PHB mutations do not appear to account for the linkage signal on 17q21-22 detected in PCGP families. Fine mapping of this region is in progress to refine the candidate region and highlight additional candidate prostate cancer susceptibility genes for sequence analysis.
Introduction
Prostate cancer has been shown to have a strong familial component leading many research teams including our own to collect multiplex prostate cancer families in order to identify the molecular basis for this common disease. However, despite the collection of many families and the formation of an international consortium (the International Consortium for Prostate Cancer Genetics or ICPCG), 1 the genes that cause hereditary prostate cancer remain elusive. This is likely due to locus heterogeneity as well as factors specific to the disease itself, including late age at diagnosis and a high background rate of sporadic cases (see review 2 ). Several linkage studies have provided evidence for a prostate cancer susceptibility gene on the long arm of chromosome 17. A genome-wide scan of 175 prostate cancer families from the University of Michigan Prostate Cancer Genetics Project (PCGP) first revealed strong suggestive evidence for linkage on chromosome 17q (LOD ¼ 2.36); the subset of pedigrees with four or more affected individuals (LOD ¼ 3.27) provided even greater evidence for linkage at this location. 3 A combined genome-wide analysis of 426 prostate cancer families, including the 175 from the PCGP, also found evidence for a prostate cancer susceptibility gene on 17q (nonparametric multipoint Kong and Cox allele-sharing LOD score ¼ 3.16 at marker D17S787; P ¼ 0.00007). 4 Most recently, a linkage signal was also detected on 17q in a combined genome-wide screen of 1233 prostate cancer families sponsored by the ICPCG (HLOD 1.99 near marker D17S1820 using a dominant mode-of-inheritance parametric model), 1 despite little evidence for this region from research teams other than the PCGP. 5 In fact, no other prostate research group in the ICPCG observed a LOD score 41.0 at 17q21 whereas the PCGP families had a HLOD score of 3.07 using the same dominant model. Taken together, there is linkage evidence for a prostate cancer susceptibility locus on 17q, and the PCGP families appear to be relatively enriched for families with mutations at this locus thus representing the optimal families for gene identification strategies.
There are a number of interesting candidate genes for inherited prostate cancer susceptibility that map to this 17q21-22 region. We previously performed full gene mutation analysis of the breast cancer susceptibility gene BRCA1 in 93 PCGP families with nonparametric linkage (NPL) scores 40 at 17q. 6 Using denaturing highperformance liquid chromatography and direct sequence analysis, we identified only one deleterious BRCA1 mutation in one man who had a family history of both prostate and ovarian cancer. This led us to conclude that there is likely one or more additional genes in this region that may be contributing to prostate cancer susceptibility.
In this report, we describe sequence analysis of the tumor suppressor gene prohibitin (PHB) in 32 PCGP families with the most significant linkage evidence at 17q (NPL score 41.0). PHB is located within 1 cM from the marker nearest the linkage peak in the 79 PCGP families with four or more confirmed cases of prostate cancer (Figure 1) . 3 PHB is thus a candidate hereditary prostate cancer susceptibility gene based on its location as well as recent data demonstrating that prohibitin is downregulated by androgens and may play a role in cell-cycle progression. 7 
Materials and methods

Patient selection
Men with prostate cancer who have at least one living affected relative were asked to participate in the University of Michigan PCGP by providing a blood sample, extended family history information, and access to medical records. All participants gave written informed consent, and all research protocols and consent forms were approved by the Institutional Review Board at the University of Michigan Medical School. Cases of prostate cancer were confirmed by medical records/ death certificates when possible. Occasionally, independent confirmation by two family members of prostate cancer in a deceased relative was used when medical records could not be obtained. Blood samples collected from affected individuals and from unaffected individuals that were informative for linkage were used. DNA was isolated from nucleated blood cells by use of the Puregene kit (Gentra Systems, Minneapolis, MN, USA). For this report, we describe results from 32 families that were determined to have an NPL score 41 at 60.1 cM on chromosome 17. This distance was selected because it represents the linkage peak for all families analyzed together.
Genetic analysis
Sequencing primers were designed to amplify all seven PHB exons including intron/exon borders and to minimize amplification of known pseudogenes ( Linkage peak in GWS for 175 PCGP families Figure 1 Location of BRCA1 (63 cM) and PHB (63.62 cM) relative to the markers used in the Prostate Cancer Genetics Project (PCGP) GWS for prostate cancer susceptibility genes (second horizontal line). The linkage peak observed when all 175 PCGP families were analyzed together was at 60.1 cM, which is closest to marker D17S1868. 3 Map distances are from The Center for Genetics at Marshfield Medical Research Foundation (www.marshmed.org/genetics). Data from the National Center for Biotechnology (www.ncbi.nlm.nih.gov) was used to place genes relative to markers. Prohibitin mutations in prostate cancer KA White et al 50 ml reaction mixture containing 5 ml 10Â buffer (Invitrogen Life Technologies, Carlsbad, CA, USA), 1 ml 50 mM MgC1 2 , 1 ml 10 mM dNTPS, 2 ml each of the two PCR primers at 5 mM concentration, 3.0 ml template DNA at 20 ng/ml, and 0.5 ml of Taq (Platinum Taq Polymerase, Invitrogen) in double-distilled H 2 O. Polymerase chain reaction amplification for each primer set was based on the maximum annealing performance and this information is available on request. Polymerase chain reaction products were cleaned for sequencing using Montage PCR Centrifugal Filter Devices (Millipore, Billerica, MA, USA). Samples were sequenced using an ABI Prism 3100 Genetic Analyzer using Big Dye Terminator v1.1 chemistries (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Sequences were analyzed using Mutation Surveyor Software (SoftGenetics, State College, PA, USA) and were reviewed by two independent researchers (KAW and AMR).
Results
In the 32 families selected for this analysis based on linkage evidence to chromosome 17q, the average number of confirmed affected family members was 4.4 (range 3-13) and the average number of affected family members in whom DNA samples were available was 2.8 (range 2-6). Genomic DNA was amplified from one affected man in each of the 32 families with evidence of linkage to chromosome 17. The youngest affected family member was selected for sequencing in 24 of 32 families.
In the remaining eight families, the second youngest affected male was sequenced based on DNA availability. Three families described themselves as African American and the remaining families were European American. The average age of prostate cancer diagnosis in the men selected for sequencing was 56.1 years (range 37-71 years). Five of the men whose DNA was sequenced had one or more additional cancers including cases of pancreas, kidney, head and neck as well as nonmelanoma skin cancer. The PHB gene is comprised of seven exons and encodes a 272 amino-acid protein. Sequencing of all seven exons and well as intron/exon junctions and the 3 0 untranslated region (3 0 UTR) from 32 men with prostate cancer from 32 unrelated multiplex prostate cancer families failed to identify any nonsynonymous or truncating mutations. A number of single nucleotide variants were identified, however, including four novel nucleotide substitutions, and these data are presented in Table 2 . No sequence variations were identified in exons.
Discussion
Prohibitin was identified in 1989 through a set of experiments in which investigators set out to identify genes that exhibit negative growth control properties. 8 The gene is highly conserved across species and is ubiquitously expressed in many tissues. 9 PHB was first suspected to play a role in human cancer based on data published by Sato et al. 10 in 1992. These investigators cloned the human homologue and mapped PHB to 17q21. They next sequenced exons 4 and 5 of PHB using somatic DNA isolated from a set of human breast cancers including cancers exhibiting allelic loss at 17q21. Four of 23 sporadic tumors were shown to have a mutation including two missense substitutions and one frameshift. 11 However, further studies by this same group identified only one additional PHB mutation out of 120 breast cancer cases and no mutations in a series of ovarian, liver and lung cancer leading the investigators to conclude that PHB is unlikely to be a common tumor suppressor gene like TP53.
More recently, a single nucleotide polymorphism (SNP) was identified in the 3 0 UTR of PHB (rs6917), and the variant T allele was shown to be associated with breast cancer susceptibility. In a case-control study in which 205 women with breast cancer were compared to 1046 geographic controls, an association was detected between the T allele and breast cancer in women with a family history of the disease (odds ratio 2.5, P ¼ 0.005). 12 Previous research suggested a functional role for this variant as the 3 0 UTR of this gene has been shown to have a regulatory function by blocking cell-cycle progression. 13 This same association was not observed with in follow-up studies of Australian women with breast cancer 14 or ovarian cancer. 15 In our report, the variant T allele was observed in five out of 64 alleles (7.8%), Abbreviation: Nr, not previously reported. For alleles, the wild-type (WT) sequence is listed first followed by the variant (V) sequence. The genotypes frequencies are presents in order: homozygous WT, heterozygous WT/V, and homozygous V/V.
Prohibitin mutations in prostate cancer KA White et al which is a lower frequency than in any of the three prior reports of women with breast or ovarian cancer or the respective control populations. [13] [14] [15] Additional studies using a case-control design should be carried out explore the potential association between the functionally important T allele and prostate cancer susceptibility.
Prohibitin has been speculated to have several different roles in the cell based on subcellular localization. As described above, prohibitin has antiproliferative properties presumably through its interaction with nuclear proteins. 16 However, confocal microscopy has been used to confirm that prohibitin is also localized in the mitochondria of the prostate cancer line LNCaP. 7 Prohibitin expression can be detected in the basal cells of normal prostate epithelium using immunohistochemistry ( Figure 2 ). The level of protein expression appears to be higher in prostatic intraepithelial neoplasia and cancer, and both cytoplasmic and nuclear staining is demonstrated. It is thought that prohibitin serves to stabilize enzymes in the mitochondria. Prohibitin may also play a role in senescence based in the observation that protein levels decline with aging (see review 16 ). In our study, we were unable to identify any clearly functional mutations in 32 men with prostate cancer from families with hereditary prostate cancer and linkage evidence to 17q. None of the variants that we identified were in exons. However, we cannot fully exclude the possibility that one or more of the variants that we identified creates a splice variant or alters transcription. Several additional limitations to our study include the limited sample size and possibility that the case selected from a given family for sequence analysis was a sporadic case based on the high frequency of disease in the general population. However, our strategy of selecting the youngest age of onset case from each family for PHB sequencing should minimize this potential bias. Direct sequence analysis of PHB is complicated by the existence of four processed pseudogenes: PHBP1 in 6q25, PHBP2 on 11p11.2, PHBP3 in 1p31.3 and PHBP4 on 2q21. 11 Use of intronic sequence primers limited contamination with pseudogene sequence which shares high homology to PHB. Finally, only approximately 50% of the promoter was sequenced as well as limited amounts of intronic sequence, therefore we cannot fully exclude the possibility of mutations in regulatory regions.
In conclusion, prostate cancer has a strong hereditary component although characterization of the genes contributing to this phenotype has been difficult. The linkage signal on 17q21-22 first detected in the University of Michigan PCGP families 3 and later found in several combined linkage studies. 4, 5 represents one of the most consistent linkage signals for hereditary prostate cancer. To date, sequence analysis has excluded both BRCA1 and PHB as likely candidate genes to explain a large number of chromosome 17-linked prostate cancer families. Fine mapping of this region using a denser panel of markers is in progress. In the meantime, testing of plausible candidate genes based on chromosomal position and function continues to be a reasonable approach for implicating genes in hereditary prostate cancer. Figure 2 Prohibitin expression in normal prostate tissue, prostatic intraepithelial neoplasia (PIN) and cancer. Using microwave antigen retrieval, formalin-fixed paraffin-embeded prostate tissue was stained with a rabbit polycloncal antibody to prohibitin (ab2996; Abcam Inc., Cambridge, MA, USA) at a titer 1:80. No staining was observed in the secretory cells of benign glands (a, normal prostate tissue), although some staining of basal cell cytoplasm was detected. Strong cytoplasmic staining was noted in PIN (b) and adenocarcinoma (c). Although most of the staining appears to be cytoplasmic, nuclear staining was occasionally observed in malignant epithelium (d).
